${p}_{I2}$ | Rate of CD8+ T cell activation induced by IL-2 | 2.4036 | day | [32] |

${g}_{I2}$ | Concentration of IL-2 necessary for half-maximal CD8+ T cell activation | $2.5036\times {10}^{3}$ | IU L | [32] |

u | Rate of inhibition of surplus CD8+ T cells induced by Treg cells in the presence of IL-2 | $2.3085\times {10}^{-13}$ | L | [49] |

$\kappa $ | Concentration of IL-2 required to halve the immunosuppressive effect of Treg cells on CD8+ T cells | $2.5036\times {10}^{3}$ | IU L | [49] |

j | Rate of activation of CD8+ T cells due to CD8+ T cell-lysed tumor cell debris | $1.245\times {10}^{-4}$ | day | [32] |

k | Tumor size required for half-maximal CD8+ T cell activation by CD8+ T cell-lysed tumor cell debris | $2.019\times {10}^{7}$ | cells | [32] |

${K}_{L}$ | Rate of CD8+ T cell depletion from chemotherapy toxicity | $4.524\times {10}^{-1}$ | day | [32] |

${\delta}_{L}$ | Coefficient of chemotherapy toxicity on CD8+ T cells | $2\times {10}^{-1}$ | L mg | [32] |

$\beta $ | Rate of circulating lymphocyte turnover | $6.3\times {10}^{-3}$ | day | [32] |

$\alpha $ | Rate of circulating lymphocyte production | $\left(3\times {10}^{9}\right)\cdot \beta $ | cells L | [32] |

${K}_{C}$ | Rate of lymphocyte depletion from chemotherapy toxicity | $5.7\times {10}^{-1}$ | day | [32] |

${\delta}_{C}$ | Coefficient of chemotherapy toxicity on circulating lymphocytes | $2\times {10}^{-1}$ | L mg | [32] |

${\mu}_{I2}$ | Rate of excretion and elimination of IL-2 | 11.7427 | day | [32] |

$\omega $ | Rate of IL-2 production from CD8+ T cells | $7.88\times {10}^{-2}$ | IU cell | [32] |

$\varphi $ | Rate of IL-2 production from circulating CD4+ and naive CD8+ T cells | $1.788\times {10}^{-7}$ | IU cell | [32] |

$\zeta $ | Concentration of IL-2 for half-maximal CD8+ T cell IL-2 production | $2.5036\times {10}^{3}$ | IU L | [32] |

${\gamma}_{1}$ | The rate of excretion and elimination of irinotecan | $4.077\times {10}^{-1}$ | day | [32] |

$\eta $ | Rate of cetuximab and panitumumab turnover and excretion | $1.386\times {10}^{-1}$ for cetuximab $9.242\times {10}^{-2}$ for panitumumab | day | [32] |